The Japan dialysis access treatment device market will grow modestly through 2029, driven by rising incidence of ESRD due to the aging population, coupled with government initiatives to improve access to dialysis care. However, market growth will be hindered to some extent due to the COVID-19 pandemic.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for dialysis access treatment products in Japan across a 10-year period.
The COVID-19 pandemic will have a negative impact on overall dialysis access procedure volumes and revenues in 2020.
What factors will contribute to the impact on dialysis access treatment device market?
To what degree will the pandemic affect different dialysis access device segments?
How soon will procedure volumes, sales, and revenues recover over the forecast period?
AVF maturation practices differ in Japan compared to other regions.
What dialysis market device segments are most affected by the short AVF maturation lengths in Japan?
How do procedure volumes in Japan differ from other global markets as a result of these unique treatment practices?
Biennial reimbursement cuts by the MHLW continue to affect the Japanese dialysis access treatment device market.
Which market segments will experience the highest cuts to reimbursement, and why?
In which segments will procedural growth compensate for ASP declines, resulting in market growth?
New technologies like percutaneous AVF catheters are expected to enter the Japan dialysis access treatment device market.
How will the expected approval of percutaneous AVF catheters affect surgical AVF procedure volumes and the use of AVGs?
- Dialysis Access Treatment Devices - Market Insights - Japan
Author(s): Bishwjit Ghoshal, MBA; Vijay Mohan Motwani
Bishwjit Ghoshal is a senior analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional oncology and vascular access device markets. Bishwjit holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali.
Follow Bishwjit on twitter: @Bishwjit_DRG
Vijay Motwani is a member of the Cardiovascular Medtech Insights team at DRG (Part of Clarivate), specializing in the dialysis access treatment device and transcatheter embolization and occlusion device markets. Vijay holds a Bachelor's degree in Pharmaceutical Sciences from Bharati Vidyapeeth Deemed University and a Master’s degree in Pharmaceutical Quality Assurance from the Manipal Academy of Higher Education, Manipal.